Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Патоморфологическая и клиническая характеристика бластной опухоли из плазмоцитоидных дендритных клеток: описание 5 собственных наблюдений. Клиническое наблюдение - Журнал Терапевтический архив №7 Vario 2022
Патоморфологическая и клиническая характеристика бластной опухоли из плазмоцитоидных дендритных клеток: описание 5 собственных наблюдений. Клиническое наблюдение
Шерстнев А.А., Ковригина А.М., Соловьева Т.И., Моисеева Т.Н. Патоморфологическая и клиническая характеристика бластной опухоли из плазмоцитоидных дендритных клеток: описание 5 собственных наблюдений. Клиническое наблюдение. Терапевтический архив. 2022;94(7):891–896.
DOI: 10.26442/00403660.2022.07.201734
DOI: 10.26442/00403660.2022.07.201734
DOI: 10.26442/00403660.2022.07.201734
________________________________________________
DOI: 10.26442/00403660.2022.07.201734
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В работе обобщены данные по диагностике пяти случаев бластной опухоли из плазмоцитоидных дендритических клеток; представлены морфологическая картина, иммунофенотип и клинические проявления данной нозологии.
Ключевые слова: бластная опухоль из плазмоцитоидных дендритных клеток, диагностика, морфология, иммуногистохимия, кожа
Keywords: blastic plasmocytoid dendritic cell neoplasm, diagnostics, histopathology, immunohistochemistry, skin
Ключевые слова: бластная опухоль из плазмоцитоидных дендритных клеток, диагностика, морфология, иммуногистохимия, кожа
________________________________________________
Keywords: blastic plasmocytoid dendritic cell neoplasm, diagnostics, histopathology, immunohistochemistry, skin
Полный текст
Список литературы
1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues (Revised 4th edition). IARC: Lyon, 2017; p. 173-8.
2. Bueno C, Almeida J, Lucio P, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica. 2004;89(1):58-69.
3. Wang H, Cao J, Hong X. Blastic plasmacytoid dendritic cell neoplasm without cutaneous lesion at presentation: case report and literature review. Acta Haematologica. 2012;127(2):124-7. DOI:10.1159/000334703
4. Trottier AM, Cerquozzi S, Owen CJ. Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects. Blood Lymphat Cancer. 2017;7:85-93. DOI:10.2147/BLCTT.S132060
5. Adachi M, Maeda K, Takekawa M, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol. 1994;47(4):278-82. DOI:10.1002/ajh.2830470406
6. Kazakov DV, Mentze T, Burg G, et al. Blastic natural killer-cell lymphoma of the skin associated with myelodysplastic syndrome or myelogenous leukaemia: a coincidence or more? Br J Dermatol. 2003;149:869-76. DOI:10.1046/j.1365-2133.2003.05639.x
7. Dzionek A, Inagaki Y, Okawa K, et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol. 2002;63(12):1133-48. DOI:10.1016/s0198-8859(02)00752-8
8. Saadeh D, Kurban M, Abbas O. Plasmacytoid dendritic cell role in cutaneous malignancies. J Dermatol Sci. 2016;83(1):3-9. DOI:10.1016/j.jdermsci.2016.05.008
9. Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873-9. DOI:10.3324/haematol.2010.026179
10. Nomburg J, Bullman S, Chung SS, et al. Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020;4(6):1006-11. DOI:10.1182/bloodadvances.2019001260
11. Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2(1):4. DOI:10.1186/2050-7771-2-4
12. Bôle-Richard E, Fredon M, Biichlé S, et al. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2020;34(12):3228-41.
DOI:10.1038/s41375-020-0777-1
13. Torres ANB, Cats D, Mei H, et al. Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. Genes Chromosomes Cancer. 2020;59(5):295-308. DOI:10.1002/gcc.22831
14. Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30(5):764-78. DOI:10.1016/j.ccell.2016.10.002
15. Sukswai N, Aung PP, Yin CC, et al. Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm. Am J Surg Pathol. 2019;43(10):1429-37. DOI:10.1097/PAS.0000000000001316
16. Agha M, Monaghan S, Swerdlow S. Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm. New England J Med. 2018;379(15):1479-81. DOI:10.1056/NEJMc1808354
17. Aung P, Sukswai N, Nejati R, et al. PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers. 2019;11:695. DOI:10.3390/cancers11050695
2. Bueno C, Almeida J, Lucio P, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica. 2004;89(1):58-69.
3. Wang H, Cao J, Hong X. Blastic plasmacytoid dendritic cell neoplasm without cutaneous lesion at presentation: case report and literature review. Acta Haematologica. 2012;127(2):124-7. DOI:10.1159/000334703
4. Trottier AM, Cerquozzi S, Owen CJ. Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects. Blood Lymphat Cancer. 2017;7:85-93. DOI:10.2147/BLCTT.S132060
5. Adachi M, Maeda K, Takekawa M, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol. 1994;47(4):278-82. DOI:10.1002/ajh.2830470406
6. Kazakov DV, Mentze T, Burg G, et al. Blastic natural killer-cell lymphoma of the skin associated with myelodysplastic syndrome or myelogenous leukaemia: a coincidence or more? Br J Dermatol. 2003;149:869-76. DOI:10.1046/j.1365-2133.2003.05639.x
7. Dzionek A, Inagaki Y, Okawa K, et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol. 2002;63(12):1133-48. DOI:10.1016/s0198-8859(02)00752-8
8. Saadeh D, Kurban M, Abbas O. Plasmacytoid dendritic cell role in cutaneous malignancies. J Dermatol Sci. 2016;83(1):3-9. DOI:10.1016/j.jdermsci.2016.05.008
9. Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873-9. DOI:10.3324/haematol.2010.026179
10. Nomburg J, Bullman S, Chung SS, et al. Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020;4(6):1006-11. DOI:10.1182/bloodadvances.2019001260
11. Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2(1):4. DOI:10.1186/2050-7771-2-4
12. Bôle-Richard E, Fredon M, Biichlé S, et al. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2020;34(12):3228-41.
DOI:10.1038/s41375-020-0777-1
13. Torres ANB, Cats D, Mei H, et al. Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. Genes Chromosomes Cancer. 2020;59(5):295-308. DOI:10.1002/gcc.22831
14. Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30(5):764-78. DOI:10.1016/j.ccell.2016.10.002
15. Sukswai N, Aung PP, Yin CC, et al. Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm. Am J Surg Pathol. 2019;43(10):1429-37. DOI:10.1097/PAS.0000000000001316
16. Agha M, Monaghan S, Swerdlow S. Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm. New England J Med. 2018;379(15):1479-81. DOI:10.1056/NEJMc1808354
17. Aung P, Sukswai N, Nejati R, et al. PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers. 2019;11:695. DOI:10.3390/cancers11050695
2. Bueno C, Almeida J, Lucio P, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica. 2004;89(1):58-69.
3. Wang H, Cao J, Hong X. Blastic plasmacytoid dendritic cell neoplasm without cutaneous lesion at presentation: case report and literature review. Acta Haematologica. 2012;127(2):124-7. DOI:10.1159/000334703
4. Trottier AM, Cerquozzi S, Owen CJ. Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects. Blood Lymphat Cancer. 2017;7:85-93. DOI:10.2147/BLCTT.S132060
5. Adachi M, Maeda K, Takekawa M, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol. 1994;47(4):278-82. DOI:10.1002/ajh.2830470406
6. Kazakov DV, Mentze T, Burg G, et al. Blastic natural killer-cell lymphoma of the skin associated with myelodysplastic syndrome or myelogenous leukaemia: a coincidence or more? Br J Dermatol. 2003;149:869-76. DOI:10.1046/j.1365-2133.2003.05639.x
7. Dzionek A, Inagaki Y, Okawa K, et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol. 2002;63(12):1133-48. DOI:10.1016/s0198-8859(02)00752-8
8. Saadeh D, Kurban M, Abbas O. Plasmacytoid dendritic cell role in cutaneous malignancies. J Dermatol Sci. 2016;83(1):3-9. DOI:10.1016/j.jdermsci.2016.05.008
9. Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873-9. DOI:10.3324/haematol.2010.026179
10. Nomburg J, Bullman S, Chung SS, et al. Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020;4(6):1006-11. DOI:10.1182/bloodadvances.2019001260
11. Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2(1):4. DOI:10.1186/2050-7771-2-4
12. Bôle-Richard E, Fredon M, Biichlé S, et al. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2020;34(12):3228-41.
DOI:10.1038/s41375-020-0777-1
13. Torres ANB, Cats D, Mei H, et al. Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. Genes Chromosomes Cancer. 2020;59(5):295-308. DOI:10.1002/gcc.22831
14. Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30(5):764-78. DOI:10.1016/j.ccell.2016.10.002
15. Sukswai N, Aung PP, Yin CC, et al. Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm. Am J Surg Pathol. 2019;43(10):1429-37. DOI:10.1097/PAS.0000000000001316
16. Agha M, Monaghan S, Swerdlow S. Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm. New England J Med. 2018;379(15):1479-81. DOI:10.1056/NEJMc1808354
17. Aung P, Sukswai N, Nejati R, et al. PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers. 2019;11:695. DOI:10.3390/cancers11050695
________________________________________________
2. Bueno C, Almeida J, Lucio P, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica. 2004;89(1):58-69.
3. Wang H, Cao J, Hong X. Blastic plasmacytoid dendritic cell neoplasm without cutaneous lesion at presentation: case report and literature review. Acta Haematologica. 2012;127(2):124-7. DOI:10.1159/000334703
4. Trottier AM, Cerquozzi S, Owen CJ. Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects. Blood Lymphat Cancer. 2017;7:85-93. DOI:10.2147/BLCTT.S132060
5. Adachi M, Maeda K, Takekawa M, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol. 1994;47(4):278-82. DOI:10.1002/ajh.2830470406
6. Kazakov DV, Mentze T, Burg G, et al. Blastic natural killer-cell lymphoma of the skin associated with myelodysplastic syndrome or myelogenous leukaemia: a coincidence or more? Br J Dermatol. 2003;149:869-76. DOI:10.1046/j.1365-2133.2003.05639.x
7. Dzionek A, Inagaki Y, Okawa K, et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol. 2002;63(12):1133-48. DOI:10.1016/s0198-8859(02)00752-8
8. Saadeh D, Kurban M, Abbas O. Plasmacytoid dendritic cell role in cutaneous malignancies. J Dermatol Sci. 2016;83(1):3-9. DOI:10.1016/j.jdermsci.2016.05.008
9. Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873-9. DOI:10.3324/haematol.2010.026179
10. Nomburg J, Bullman S, Chung SS, et al. Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2020;4(6):1006-11. DOI:10.1182/bloodadvances.2019001260
11. Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2(1):4. DOI:10.1186/2050-7771-2-4
12. Bôle-Richard E, Fredon M, Biichlé S, et al. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2020;34(12):3228-41.
DOI:10.1038/s41375-020-0777-1
13. Torres ANB, Cats D, Mei H, et al. Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. Genes Chromosomes Cancer. 2020;59(5):295-308. DOI:10.1002/gcc.22831
14. Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30(5):764-78. DOI:10.1016/j.ccell.2016.10.002
15. Sukswai N, Aung PP, Yin CC, et al. Dual expression of TCF4 and CD123 is highly sensitive and specific for blastic plasmacytoid dendritic cell neoplasm. Am J Surg Pathol. 2019;43(10):1429-37. DOI:10.1097/PAS.0000000000001316
16. Agha M, Monaghan S, Swerdlow S. Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm. New England J Med. 2018;379(15):1479-81. DOI:10.1056/NEJMc1808354
17. Aung P, Sukswai N, Nejati R, et al. PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers. 2019;11:695. DOI:10.3390/cancers11050695
Авторы
А.А. Шерстнев*, А.М. Ковригина, Т.И. Соловьева, Т.Н. Моисеева
ФГБУ «Национальный медицинский исследовательский институт гематологии» Минздрава России, Москва, Россия
*sherstnevandrejj@mail.ru
National Research Center for Hematology, Moscow, Russia
*sherstnevandrejj@mail.ru
ФГБУ «Национальный медицинский исследовательский институт гематологии» Минздрава России, Москва, Россия
*sherstnevandrejj@mail.ru
________________________________________________
National Research Center for Hematology, Moscow, Russia
*sherstnevandrejj@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.